Protalix BioTherapeutics (PLX) Depreciation Expense (2024 - 2026)

Protalix BioTherapeutics has reported Depreciation Expense for 3 years, with the latest figure at $404000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation Expense rose 16.76% year-over-year to $404000.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 14.68% YoY), and the FY2025 full-year result was $1.5 million, up 12.35% from the prior year.
• Depreciation Expense for Q1 2026 stood at $404000.0, up from $387000.0 in the prior quarter.
• The five-year high for Depreciation Expense was $404000.0 in Q1 2026, with the low at $319000.0 in Q2 2024.
• Average Depreciation Expense over 3 years is $356375.0, with a median of $353000.0 recorded in 2025.
• Year-over-year, Depreciation Expense rose 12.85% in 2025 and rose 16.76% in 2026.
• Tracing PLX's Depreciation Expense over 3 years: stood at $334000.0 in 2024, then climbed by 15.87% to $387000.0 in 2025, then increased by 4.39% to $404000.0 in 2026.
• The last three Depreciation Expense figures came in at $404000.0 (Q1 2026), $387000.0 (Q4 2025), and $372000.0 (Q3 2025), per Business Quant data.

Peer Comparison